PDS01ADC

PDS01ADC 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Cancer Of Prostate。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。

正在招募患者的 PDS01ADC 研究

• A Phase I/II Study of PDS01ADC With Docetaxel and Abiraterone in Adults With Metastatic Castration Sensitive and PDS01ADC With Docetaxel in Castration Resistant Prostate Cancer

  I 期 / II 期招募中美国NCT04633252

• A Phase II Study Evaluating T-Cell Clonality After Stereotactic Body Radiation Therapy Alone and in Combination With the Immunocytokine PDS01ADC in Localized High and Intermediate Risk Prostate Cancer Treated With Androgen Deprivation Therapy

  II 期招募中美国NCT05361798

• Enzalutamide and PDS01ADC in PET Positive Recurrent Prostate Cancer (pprPC) Without Testosterone Lowering Therapy

  II 期招募中美国NCT06096870

• PDS01ADC in Combination With Hepatic Artery Infusion Pump (HAIP) and Systemic Therapy for Subjects With Metastatic Colorectal Cancer, Intrahepatic Cholangiocarcinoma, or Metastatic Adrenocortical Carcinoma

  II 期招募中美国NCT05286814

• PDS01ADC Monotherapy and in Combination With M7824 in Advanced Kaposi Sarcoma

  I 期 / II 期招募中美国NCT04303117

本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。